NVCT — Nuvectis Pharma Balance Sheet
0.000.00%
- $116.19m
- $96.73m
Annual balance sheet for Nuvectis Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Cash and Equivalents | ||||
Cash and Short Term Investments | 0 | 5.74 | 20 | 19.1 |
Total Other Current Assets | ||||
Total Current Assets | 0 | 5.83 | 20.4 | 19.2 |
Other Long Term Assets | ||||
Total Assets | 0 | 6.66 | 20.4 | 19.2 |
Accounts Payable | ||||
Accrued Expenses | ||||
Notes Payable / Short Term Debt | ||||
Total Other Current Liabilities | ||||
Total Current Liabilities | 0.01 | 2.42 | 6.19 | 6.98 |
Total Long Term Debt | ||||
Total Debt | ||||
Total Other Liabilities | ||||
Total Liabilities | 0.01 | 2.42 | 6.19 | 6.98 |
Non Redeemable Preferred Stock | ||||
Common Stock | ||||
Additional Paid In Capital | ||||
Retained Earnings (Accumulated Deficit) | ||||
Other Equity | ||||
Total Equity | -0.01 | 4.24 | 14.2 | 12.2 |
Total Liabilities & Shareholders' Equity | 0 | 6.66 | 20.4 | 19.2 |
Total Common Shares Outstanding |